Lifestance Health Group Inc
NASDAQ:LFST

Watchlist Manager
Lifestance Health Group Inc Logo
Lifestance Health Group Inc
NASDAQ:LFST
Watchlist
Price: 6.32 USD -5.53%
Market Cap: $2.5B

Lifestance Health Group Inc
Investor Relations

LifeStance Health Group Inc., emerging as a prominent player in the rapidly evolving behavioral health sector, operates with a mission to positively impact the lives of individuals facing mental health challenges across the United States. Founded in 2017, the company recognized the increasing demand for accessible, high-quality mental health services amidst a backdrop of rising awareness and destigmatization of mental health issues. LifeStance Health offers a comprehensive range of services, including therapy, psychiatric evaluations, and medication management. It facilitates these services both online through telehealth platforms and in-person at a multitude of clinics, effectively bridging the gap between patients and care providers. The adaptability of their hybrid model not only expands their reach but also caters to varying patient needs, particularly crucial in a post-pandemic world where digital solutions have become indispensable.

LifeStance Health generates revenue through a fee-for-service business model, deriving income primarily from patient billing and insurance reimbursements. The company's network comprises a diverse array of licensed therapists, psychiatrists, and psychologists who deliver personalized care, thus operating both as salaried employees and through revenue-sharing arrangements at their numerous practice locations. By scaling a vast provider network, LifeStance maintains significant leverage with insurance companies, negotiating favorable reimbursement rates which are central to its revenue strategy. Additionally, the organization benefits from being at the forefront of mental health service delivery innovations, which positions it strategically to adapt and grow in a marketplace that increasingly values integration of mental health into broader healthcare frameworks.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Feb 25, 2026
AI Summary
Q4 2025

Revenue Beat: LifeStance reported Q4 revenue of $382 million, up 17% year-over-year, surpassing expectations due to higher revenue per visit and visit volumes.

Profitability Milestones: The company achieved double-digit adjusted EBITDA margins for the full year for the first time as a public company and delivered positive net income and EPS a year ahead of plan.

Strong Cash Generation: Free cash flow reached $110 million for 2025, exceeding expectations, with a solid balance sheet and ample financial flexibility.

2026 Guidance: Management expects 2026 revenue of $1.615–$1.655 billion, continued center margin expansion, and adjusted EBITDA of $185–$205 million.

Share Repurchase: A new $100 million share repurchase program was announced, to be funded by cash on hand.

Operational Improvements: Productivity initiatives—including technology and incentive programs—drove a 7% increase in visits per clinician and are expected to remain durable into 2026.

Technology & AI Investments: Digital and AI tools improved scheduling, patient conversion, documentation, and operational efficiency, with further expansion planned in 2026.

Specialty Services Growth: Specialty revenue targeted to grow about 40% in 2026, driven by services for treatment-resistant depression and other advanced offerings.

Key Financials
Revenue
$382 million
Revenue
$1.424 billion
Visit Volume
2.4 million visits (Q4)
Visit Volume
nearly 9 million visits (2025)
Clinician Base
8,040 clinicians (end of 2025)
Net Clinician Adds
657 (full year 2025)
Visit per Average Clinician
up 7% year-over-year (Q4)
Revenue per Visit
$160
Center Margin
$126 million (Q4)
Center Margin
$461 million (2025 full year)
Center Margin Percentage
33% (Q4)
Adjusted EBITDA
$49 million (Q4)
Adjusted EBITDA Margin
12.8% (Q4)
Adjusted EBITDA
$158 million (2025 full year)
Adjusted EBITDA Margin
11.1% (2025 full year)
Net Income
positive (2025 full year)
Earnings Per Share
positive (2025 full year)
Free Cash Flow
$47 million (Q4); $110 million (2025 full year)
Cash Position
$249 million (end of Q4 2025)
Net Long-Term Debt
$266 million
Undrawn Revolver
$100 million
Net Leverage Ratio
0.2x
Gross Leverage Ratio
1.8x
Share Repurchase Program
$100 million authorization
Specialty Revenue
targeting $70 million in 2026
New Centers Opening
20 to 30 expected in 2026
Earnings Call Recording
Other Earnings Calls

Management

Mr. Kenneth Alan Burdick
CEO & Chairman
No Bio Available
Mr. David Patrick Bourdon
Chief Financial Officer & Treasurer
No Bio Available
Mr. Pablo Pantaleoni
Chief Digital Officer
No Bio Available
Ms. Monica Prokocki
Vice President of Investor Relations
No Bio Available
Brooke Matthews
Director of Public Relations
No Bio Available
Ms. Ann Varanakis
Chief People Officer
No Bio Available
Dr. Ujjwal Ramtekkar CPE, M.B.A., M.D.
Chief Medical Officer
No Bio Available
Mr. Richard Hall
Executive Vice President of Shared Services
No Bio Available
Ms. Lisa Keise Miller
Executive Vice President of Practice Operations
No Bio Available
Ms. Toi Valentine
Senior VP & Chief Strategy Officer
No Bio Available

Contacts

Address
ARIZONA
Scottsdale
4800 N. Scottsdale Road, Suite 6000
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett